| 1 |
司念，李可，魏晴．体外膜肺氧合支持下的输血策略[J]．临床输血与检验，2021，23(4)：412-415.
|
| 2 |
曹志龙，田李均，徐俊贤，等．体外膜肺氧合治疗危重症患者的临床分析[J]．东南国防医药，2021，23(5)：525-527.
|
| 3 |
李小兵，沈立，李佳，等．体外膜氧合技术在儿童先天性心脏病术后的临床应用[J]．中国心血管病研究，2022，20(2)：108-112.
|
| 4 |
吴锋，杨秋林，张小文，等．体外膜氧合成功救治重度有机氟中毒4例报道[J]．中华急诊医学杂志，2022，31(2)：223-227.
|
| 5 |
杨俭新，周光居，徐小琴，等．严重创伤后并发ARDS行ECMO治疗46天1例报告[J]．中华急诊医学杂志，2022，31(4)：559-561.
|
| 6 |
Le Gall A，Follin A，Cholley B，et al.Veno-arterial-ECMO in the intensive care unit：from technical aspects to clinical practice[J]．Anaesth Crit Care Pain Med，2018，37(3)：259-268.
|
| 7 |
Singh G，Hudson D，Shaw A．Medical optimization and liberation of adult patients from VA-ECMO[J]．Can J Cardiol，2020，36(2)：280-290.
|
| 8 |
Chandler WL.Coagulation activation during extracorporeal membrane oxygenation (ECMO)[J]．Thromb Res，2022(211)：154-160.
|
| 9 |
Wiegner R，Chakraborty S，Huber-Lang M．Complement-coagulation crosstalk on cellular and artificial surfaces[J]．Immunobiology，2016，221(10)：1073-1079.
|
| 10 |
Xu LC，Bauer JW，Siedlecki CA.Proteins，platelets，and blood coagulation at biomaterial interfaces[J]．Colloids Sur B Biointerfaces，2014，124(1)：49-68.
|
| 11 |
朱建兵，张俊峰．血小板糖蛋白IIb/IIIa受体拮抗剂在急性冠脉综合征应用研究的进展[J]．心血管康复医学杂志，2015，5(1)：88-91.
|
| 12 |
Cartwright B，Bruce HM，Kershaw G，et al.Hemostasis，coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation：the HECTIC study[J]．Sci Rep，2021，11(1)：7975.
|
| 13 |
Gremmel T，Frelinger AL 3rd，Michelson AD.Platelet physiology[J]．Semin Thromb Hemost，2016，42(3)：191-204.
|
| 14 |
Delmas C，Jacquemin A，Vardon-Bounes F，et al.Anticoagulation monitoring under ECMO support：a comparative study between the activated coagulation time and the Anti-Xa activity assay[J]．J Intensive Care Med，2020，35(7)：679-686.
|
| 15 |
Erdem Ö，Kuiper JW，Houmes RJ，et al.Coagulation complications after conversion from roller to centrifugal pump in neonatal and pediatric extracorporeal membrane oxygenation[J]．J Pediatr Surg，2021，56(8)：1378-1385.
|
| 16 |
Buchtele N，Schwameis M，Schellongowski P，et al.Prevalence and clinical impact of reduced coagulation factor XII activity in patients receiving extracorporeal membrane oxygenation[J]．Crit Care Med，2021，49(12)：e1206-e1211.
|
| 17 |
Wang L，Shao J，Fan E，et al.Disseminated intravascular coagulation score is related to short-term mortality in patients undergoing venoarterial extracorporeal membrane oxygenation after cardiac surgery[J]．ASAIO J，2021，67(8)：891-898.
|
| 18 |
Drop J，Van Den Helm S，Monagle P，et al.Coagulation in pediatric extracorporeal membrane oxygenation：a systematic review of studies shows lack of standardized reporting[J]．Res Pract Thromb Haemost，2022，6(2)：e12687.
|
| 19 |
Dalton HJ，Reeder R，Garcia-Filion P，et al.Eunice kennedy shriver national institute of child health and human development collaborative pediatric critical care research network.factors associated with bleeding and thrombosis in children receiving extracorporeal membrane oxygenation[J]．Am J Respir Crit Care Med，2017，196(6)：762-771.
|
| 20 |
Mazzeffi M，Greenwood J，Tanaka K，et al.Bleeding，transfusion，and mortality on extracorporeal life support：ECLS working group on thrombosis and hemostasis[J]．Ann Thorac Surg，2016，101(2)：682-689.
|
| 21 |
Lorusso R，Gelsomino S，Parise O，et al.Neurologic injury in adults supported with veno-venous extracorporeal membrane oxygenation for respiratory failure：findings from the extracorporeal life support organization database[J]．Crit Care Med，2017，45(1)：1389-1397.
|
| 22 |
Lorusso R，Barili F，Mauro MD，et al.In-hospital neurologic complications in adult patients undergoing venoarterial extracorporeal membrane oxygenation：results from the extracorporeal life support organization registry[J]．Crit Care Med，2016，44(10)：e964-e972.
|
| 23 |
Kaseer H，Soto-Arenall M，Sanghavi D，et al.Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation[J]．J Card Surg，2020，35(4)：779-786.
|
| 24 |
Masaki K，Hashimoto T，Katsuki M，et al.Fatal pulmonary hemorrhagic infarction caused by pulmonary vein thrombotic occlusion during venoarterial extracorporeal membrane oxygenation[J]．Int Heart J，2021，62(5)：1182-1185.
|
| 25 |
Bhat AG，Golchin A，Pasupula DK，et al.Right sided intracardiac thrombosis during veno-arterial extracorporeal membrane oxygenation：a case report and literature review[J]．Case Rep Crit Care，2019，2019(1)：1-5.
|
| 26 |
席绍松，朱英，胡炜．静脉-动脉体外膜氧合支持患者的左心减负[J/CD]．中华重症医学电子杂志(网络版)，2020，6(2)：132-139.
|
| 27 |
Parzy G，Daviet F，Persico N，et al.Prevalence and risk factors for thrombotic complications following venovenous extracorporeal membrane oxygenation：A CT scan study[J]．Crit Care Med，2020，48(2)：192-199.
|
| 28 |
Ranucci M，Cotza M，Isgrò G，et al.Anti-factor xa-based anticoagulation during extracorporeal membrane oxygenation：potential problems and possible solutions[J]．Semin Thromb Hemost，2020，46(4)：419-427.
|
| 29 |
Appelt H，Philipp A，Mueller T，et al.Factors associated with hemolysis during extracorporeal membrane oxygenation(ECMO)-Comparison of VA-versus VV ECMO[J]．PLoS One，2020，15(1)：e0227793.
|
| 30 |
Thiagarajan RR，Barbaro RP，Rycus PT，et al.Extracorporeal life support organization registry international report 2016[J]．ASAIO J，2017，63(1)：60-67.
|
| 31 |
张洋，邓磊，冯璇璘，等．体外膜肺氧合治疗中不同抗凝策略与并发症的分析[J]．中国急救医学，2021，41(7)：630-634.
|
| 32 |
Horton S，Augustin S．Activated clotting time(ACT)[J]．Methods Mol Biol，2013，992(1)：155-67.
|
| 33 |
Baglin T，Barrowcliffe TW，Cohen A，et al.Guidelines on the use and monitoring of heparin[J]．Br J Haematol，2006，133(1)：19-34.
|
| 34 |
Koster A，Ljajikj E，Faraoni D．Traditional and non-traditional anticoagulation management during extracorporeal membrane oxygenation[J]．Ann Cardiothorac Surg，2019，8(1)：129-136.
|
| 35 |
Ranucci M，Cotza M，IsgròG，et al.Anti-factor xa-based anticoagulation during extracorporeal membrane oxygenation：potential problems and possible solutions[J]．Semin Thromb Hemost，2020，46(4)：419-427.
|
| 36 |
Colman E，Yin EB，Laine G，et al.Evaluation of a heparin moni-toring protocol for extracorporeal membrane oxygenation and review of the literature[J]．J Thorac Dis，2019，11(8)：3325-3335.
|
| 37 |
Anderson JAM，Saenko EL.Heparin resistance[J]．Br J Anaesth，2002，88(4)：467-469.
|
| 38 |
Cosmi B，Fredenburgh JC，Rischke J，et al.Effect of nonspecific binding to plasma proteins on the antithrom-bin activities of unfractionated heparin，low-molecular-weight hep-arin，and dermatan sulfate[J]．Circulation，1997，95(1)：118-124.
|
| 39 |
Lee CJ，Ansell JE.Direct thrombin inhibitors[J]．Br J Clin Pharmacol，2011，72(4)：581-592.
|
| 40 |
Hepner M，Karlaftis V．Antithrombin[J]．Methods Mol Biol，2013，992(1)：355-364.
|
| 41 |
Hogan M，Berger JS.Heparin-induced thrombocytopenia(HIT)：review of incidence，diagnosis，and management[J]．Vasc Med，2020，25(2)：160-173.
|
| 42 |
Panigada M，Spinelli E，Cucino A，et al.Antithrombin supplemen-tation during extracorporeal membrane oxygenation：study protocol for a pilot randomized clinical trial[J]．Trials，2019，20(1)：349.
|
| 43 |
Choi JH，Luc JGY，Weber MP，et al.Heparin-induced thrombocyto-penia during extracorporeal life support：incidence，management and outcomes[J]．Ann Cardiothorac Surg，2019，8(1)：19-31.
|
| 44 |
Robson R，White H，Aylward P，et al.Bivalirudin pharma-cokinetics and pharmacodynamics：effect of renal function，dose，and gender[J]．Clin Pharmacol Ther，2002，71(1)：433-439.
|
| 45 |
Pappalardo F，Maj G，Scandroglio A，et al.Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocy-topenia：the immune reaction appeared to continue unabated[J]．Perfusion，2009，24(1)：135-137.
|
| 46 |
Walker EA，Roberts AJ，Louie EL，et al.Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy[J]．ASAIO J，2019，65(2)：134-138.
|
| 47 |
Jyoti A，Maheshwari A，Daniel E，et al.Bivalirudin in venovenous extracorporeal membrane oxygenation[J]．J Extra Corpor Technol，2014，46(1)：94-97.
|
| 48 |
Pieri M，Agracheva N，Bonaveglio E，et al.Bivalirudin versus hep-arin as an anticoagulant during extracorporeal membrane oxygena-tion：a case-control study[J]．J Cardiothorac Vasc Anesth，2013，27(1)：30-34.
|
| 49 |
Berei TJ，Lillyblad MP，Wilson KJ，et al.Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation[J]．ASAIO J，2018，64(1)：623-629.
|
| 50 |
Ranucci M，Ballotta A，Kandil H，et al.Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracor-poreal membrane oxygenation[J]．Crit Care，2011，15(1)：R275.
|
| 51 |
Cardinale M，Ha M，Liu MH，Reardon DP.Direct thrombin inhib-itor resistance and possible mechanisms[J]．Hosp Pharm，2016，51(11)：922-927.
|
| 52 |
Kennedy DM，Alaniz C．Apparent argatroban resistance in a patient with elevated factor VIII levels[J]．Ann Pharmacother，2013，47(7-8)：e29.
|
| 53 |
Menk M，Briem P，Weiss B，et al.Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support[J]．Ann Intensive Care，2017，7(1)：82.
|
| 54 |
Esper SA，Welsby IJ，Subramaniam K，et al.Adult extracorporeal membrane oxygenation：an international survey of transfusion and anticoagulation techniques[J]．Vox Sang，2017，112(2)：443-452.
|